Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Brian A Jonas
University of California, Davis
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucsf-Fresno
Clovis, California, United States
Mohammed Bukari, MDRecruiting - Ucla / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Caspian OliaiNot, yet, recruiting - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Brian A. JonasRecruiting - University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Matthew J. WieduwiltNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Feb 2022
- Primary completion
- 1 May 2025
- Completion
- 1 Dec 2025
- Last update posted
- 29 May 2024
- Registered enrollment
- 20
- Registry id
- NCT04905810
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.